Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Willi Kreis"'
Publikováno v:
Cancer Investigation. 21:400-417
Androgens play a critical role not only in the physiological development of the prostate but also in the genesis of prostate cancer. The effects of androgen on the prostate gland and on the other tissues of the body are mediated by activation of the
Publikováno v:
Anti-Cancer Drugs. 13:1011-1016
Microtubulin binding agents such as docetaxel have significant preclinical and clinical activity in the treatment of hormone-refractory prostate cancer. We have previously used median-effect analysis to define both synergistic and antagonistic drug c
Autor:
Daniel R. Budman, Vincent Vinciguerra, Peter Zervos, Steven C. Ernest, Jonathan E. Kolitz, Steven L. Allen, Robert B. Johnson, Jackie Walling, Ronald R. Bowsher, Willi Kreis, Barbara Barile
Publikováno v:
Cancer Chemotherapy and Pharmacology. 47:525-531
Purpose: In this phase I trial in humans the safety and pharmacology of LY309887 on a weekly schedule combined with daily oral 5-mg doses of folic acid were evaluated. Background: LY309887 is an inhibitor of folate-dependent enzymes involved in de no
Publikováno v:
Cancer Chemotherapy and Pharmacology. 47:78-82
Background: The cyclosporins have been thought as being mainly immunosuppressive agents which interfere with the function of the MDR pump and thus play a role in resistance to drug anticancer effects. We reexamined their cytotoxicity in defined cell
Autor:
Daniel R. Budman, Xiao M. Liu, Lily Stiel, Anthony Calabro, Long G. Wang, Laurel M. Adams, Willi Kreis
Publikováno v:
Cancer Investigation. 18:695-701
Empiric combinations of vinca alkaloids with taxanes have been recently used in clinical oncology. To enhance the activity of these two classes of agents, we evaluated the sequence and duration of exposure, looking for synergistic effects. Cell lines
Publikováno v:
Biochemical Pharmacology. 58:1115-1121
Estramustine phosphate has been used frequently alone or in combination with other drugs for the treatment of hormone-refractory prostate cancer. Estramustine is one of the major active metabolites of estramustine phosphate in vivo. We recently demon
Publikováno v:
Anti-Cancer Drugs. 9:697-702
New cytotoxics with significant activity both in preclinical and clinical situations continued to be applied in the clinic by empiric means. The use of defined cell lines allows unanticipated antagonism between agents to be identified and to suggest
Publikováno v:
British Journal of Urology. 79:196-202
Objective To evaluate combinations of anti-tumour agents in tissue cultures using three established cell lines derived from patients with prostate cancer to obtain potential candidates for therapeutic testing in patients with prostate cancer. Materia
Autor:
Stephen W. Hall, Willi Kreis, S. Peter Ouyang, Jane Wu, Alton B. Kremer, Donald L. Trump, E. James Seidmon, Michael R. Kurman
Publikováno v:
Annals of Surgical Oncology. 2:550-556
Background: Liarozole binds to the cytochrome P-450-dependent hydroxylating enzymes involved in steroid biosynthesis and retinoic acid catabolism. This phase I study investigated the clinical/endocrine toxicity profile of liarozole and determined the
Autor:
Jonathan H. Marsh, Willi Kreis, Linda C. DeMarco, Daniel R. Budman, Barbara Barile, Philip Schulman, Steven L. Allen, Silvia Akerman, Michael W. Schuster
Publikováno v:
Cancer Chemotherapy and Pharmacology. 31:481-484
Eight patients, of whom four had acute myeloid leukemia (AML) and four had chronic myeloid leukemia (CML) blast crisis, were treated with a combination of cytosine arabinoside (ARA-C: 1,600 mg/m2 in three patients, 1,200 mg/m2 in five patients), tetr